Brookline initiated coverage of Ernexa Therapeutics with a Buy rating and $30 price target. Ernexa is engineering induced pluripotent stem cells and transforming them into induced mesenchymal stem cells in a \"novel immune-oncology approach\" to treating solid tumors and autoimmune diseases, the analyst tells investors. The firm sees the risk/reward becoming favorable as ERNA-101 and ERNA-202 advance through the clinic, the analyst added.
